icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm

Boris Johnson names business minister Nadhim Zahawi top UK official responsible for vaccine deployment

Boris Johnson names business minister Nadhim Zahawi top UK official responsible for vaccine deployment
UK Conservative Party politician Nadhim Zahawi has been appointed as under secretary of state responsible for the deployment of a Covid-19 vaccine across the country, signalling a massive vaccination programme is forthcoming.

The prime minister’s office said Zahawi’s new position is temporary and will last until at least next summer.

According to UK media, Zahawi is expected to oversee the rollout of a vaccine across the country once it is approved. He will report to Health Secretary Matt Hancock. 

Zahawi has served as parliamentary under secretary of state at the Department for Business, Energy and Industrial Strategy since 2019, and will retain this portfolio.

On Friday, Zahawi said he was “extremely disappointed and sad” that his constituency in Warwickshire was slated to be moved to Tier 3 quarantine restrictions next week. He warned the stricter lockdown will cripple the area’s economy, especially its tourism industry. 

Also on rt.com London asks regulator to assess Oxford/AstraZeneca Covid-19 vaccine amid concerns over trial’s robustness

Earlier this week, the government asked the country’s medical regulator to provide its opinion on the Covid-19 vaccine developed by the British-Swedish company AstraZeneca and the University of Oxford. If authorised, the company is expected to produce up to four million doses for the UK by the end of the year and 40 million by the end of March, officials said.

The vaccine’s trials brought some concerns when it was revealed that its 90 percent efficacy rate was demonstrated in a group consisting of people younger than 55. At the same time, in a group that included people older than 55, the reported efficacy rate was 62 percent.

Think your friends would be interested? Share this story!